Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O5 |
Molecular Weight | 270.2369 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C2C(=O)\C(OC2=C1)=C\C3=CC(O)=C(O)C=C3
InChI
InChIKey=RGNXWPVNPFAADO-NSIKDUERSA-N
InChI=1S/C15H10O5/c16-9-2-3-10-13(7-9)20-14(15(10)19)6-8-1-4-11(17)12(18)5-8/h1-7,16-18H/b14-6-
Sulfuretin, one of the major flavonoid glycosides found in the stem bark of Albizzia julibrissin and heartwood of Rhus verniciflua, is a known anti-oxidant. Sulfuretin is also known to have anti-inflammatory effects. Sulfuretin suppressed the chemokine production, matrix metalloproteinase secretion, and cell proliferation induced by tumor necrosis factor-α in rheumatoid FLS. In addition, sulfuretin inhibited the osteoclast differentiation induced by macrophage colony-stimulating factor and receptor activator of NF-κB ligand in bone marrow macrophages. In mice with CIA, early intervention with sulfuretin prevented joint destruction, as evidenced by a lower cumulative disease incidence and an absence of diverse disease features based on hind paw thickness, radiologic and histopathologic findings, and inflammatory cytokine levels. In mice with established arthritis, sulfuretin treatment significantly reduced synovial inflammation and joint destruction. The in vitro and in vivo protective effects of sulfuretin were mediated by inhibition of the NF-κB signaling pathway.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14648391
Rats: Oral administration (30 mg/kg) of sulfuretin and fustin, which were isolated from the EtOAc extract by activity-guided separation, significantly decreased RA and CRP factors.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22521292
RA-FLS (2 × 10(6) cells) were pretreated with 30 uM sulfuretin for 1 h and then treated with TNF-α (10 ng/ml). Pretreatment
with sulfuretin significantly diminished TNF-α-mediated
chemokines production in a concentration-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
120-05-8
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
DTXSID30877681
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
204-366-4
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
C054989
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
5281295
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
9355
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
M6410VY6MI
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | |||
|
m10372
Created by
admin on Sat Dec 16 01:37:39 GMT 2023 , Edited by admin on Sat Dec 16 01:37:39 GMT 2023
|
PRIMARY | Merck Index |
PARENT (METABOLITE)
SUBSTANCE RECORD